型号:
产品价格:电议      采购度:1608      原产地:美洲
发布时间:2021/7/29 16:10:33 所属地区:上海 上海市
简要描述:
OPC-167832 是一种有效的口服活性 dprE1 抑制剂,其>IC50 为 μM。OPC-167832 具有抗结核活性,可用于由结核分枝杆菌引起的结核病的相关研究。
标签:opc
产品详情
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 1883747-71-4
MCE 站:OPC-167832
产品活性:OPC-167832 是一种有效的口服活性 dprE1 抑制剂,其>IC50 为 0.258 μM。OPC-167832 具有抗结核活性,可用于由结核分枝杆菌引起的结核病的相关研究。
研究领域:Anti-infection
作用靶点:Bacterial
In Vitro: OPC-167832 exhibits very low MICs against laboratory strains of?M. tuberculosis?H37Rv (MIC: 0.0005 μg/ml) and Kurono (MIC: 0.0005 μg/ml) and strains with monoresistance to rifampin (RIF), isoniazid (INH), ethambutol (EMB), streptomycin (STR), and pyrazinamide (PZA) (MIC: 0.00024-0.001 μg/ml). However, OPC-167832 has minimal or no activity against standard strains of nonmycobacterial aerobic and anaerobic bacteria.The IC90 values of OPC-167832 against intracellular M. tuberculosis strains H37Rv and Kurono are 0.0048 and 0.0027?μg/ml, respectively. OPC-167832 shows bactericidal activity against intracellular M. tuberculosis at a low concentration, and the bactericidal activity is saturated at concentrations of 0.004?μg/ml or higher.
In Vivo: OPC-167832 (oral administration; 0.625-10 mg/kg) exhibits a good pharmacokinetic??characteristic. The plasma reaches peak at 0.5 h to 1.0 h (tmax) and is eliminated with a half-life (t1/2) of 1.3 h to 2.1 h?OPC-167832 distribution in the lungs is approximately 2 times higher than that in plasma, and the?Cmax?and AUCt of OPC-167832 in plasma and the lungs shows dose dependency.OPC-167832 (oral administration; 0.625-10 mg/kg; 4?weeks) significantly reduces lung CFU compared to the vehicle group. The dose-dependent decrease of lung CFU is observed from 0.625?mg/kg to 2.5?mg/kg. In a?M. tuberculosis?Kurono-infected ICR female mice model. OPC-167832 combines with DMD, BDQ, or LVX via oral gavage exhibits significantly higher efficacies than each single agent alone..OPC-167832 (oral gavage; 2.5?mg/kg; combination with DCMB; 12 weeks) demonstrates the most potent efficacy when compares with DC, DCB. The lung CFU count after 6 weeks of treatment is below the detection limit, and at the end of just 8 weeks of treatment, the bacteria in the lungs of all the evaluated mice had already been eradicate.
相关产品:Doxorubicin hydrochloride | Bafilomycin A1 | Puromycin dihydrochloride | Staurosporine | Dexamethasone | Doxycycline (hyclate) | Actinomycin D | G-418 disulfate | 5-Azacytidine | Etoposide | Mitomycin C | CCCP | Nigericin sodium salt | Resveratrol | Tunicamycin | Hygromycin B | Tacrolimus | Ionomycin | Vancomycin hydrochloride | Streptozocin | Tanespimycin | Anisomycin | Neomycin sulfate | Ampicillin sodium | Geldanamycin | Auranofin | Daunorubicin hydrochloride | Metronidazole | Minocycline hydrochloride | Gentamicin sulfate
品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物,我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物;
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果;
• 专业团队跟踪*新的制药及生命科学研究进展,为您提供全球*新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。
更新时间:2024/1/2 10:17:03
留言咨询
温馨提示
1.遵守中华人民共和国有关法律、法规,尊重网上道德,承担一切因您的行为而直接或间接引起的法律责任。
2.请您真实的反映产品的情况,不要捏造、诬蔑、造谣。如对产品有任何疑问,也可以留言咨询。
3.未经本站同意,任何人不得利用本留言簿发布个人或团体的具有广告性质的信息或类似言论。
相关新闻
相关产品